Shanghai Junshi Biosciences Co., Ltd. announced that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the "FDA") concerning the approval of the investigational new drug ("IND") application for XPO1 inhibitor WJ01024 tablets (product code: "JS110") by the FDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.28 HKD | -1.91% | -3.92% | -41.98% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.98% | 3.35B | |
+2.22% | 93.53B | |
-1.71% | 38.27B | |
-12.83% | 32.84B | |
-12.14% | 16.08B | |
-0.68% | 14.02B | |
-12.63% | 11.47B | |
+163.45% | 9.92B | |
-53.23% | 9.42B | |
+3.52% | 8.98B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)